Biotechnology company Edison Oncology (EOHC.US) plans to go public in the United States, raising $25 million. The IPO is priced at $8-10 per share.

The biotechnology company Edison Oncology, dedicated to developing targeted small molecule cancer therapies, submitted its initial public offering (IPO) application to the US Securities and Exchange Commission (SEC) last Friday, planning to issue 2.8 million shares of stock at $8-10 per share, raising up to $25 million. The company plans to list on the New York Stock Exchange with the stock code "EOHC." Edison Oncology is a clinical-stage biotechnology company focused on developing oncology small molecule candidate drugs, with research projects in formulation improvement, repurposing of existing drugs, and exploring new mechanisms of action. Their product pipeline includes early-stage assets targeting ARID1A mutant cancers, the replication stress pathway, ErbB-driven tumors, and pediatric solid tumors. The company advances its research through traditional and 505(b)(2) regulatory pathways, conducting early-stage studies to assess safety, pharmacokinetics, and preliminary anti-tumor activity. Data shows that the company had a revenue of $446,000 in the 12-month period ending on September 30, 2025.